TRACON Pharmaceuticals (aka TRACON PHARMA) is Profiled in this Database

Updated At 28 Dec, 2012

Start Free 7 Day Trial Now
Partial description of this company
1-TRC105 is a Phase 2 monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis; it is expected to complement chemotherapy and treatment with VEGF inhibitors, including Avastin(R) or Lucentis(R). 2-TRC102 is a Phase 2 ready small molecule inhibitor of base excision repair that reverses resistance to antimetabolite and alkylating agent chemotherapies

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of TRACON Pharmaceuticals (aka TRACON PHARMA) plus 5035 other startups.

Start Free 7 Day Trial Now

Learn More About TRACON Pharmaceuticals (aka TRACON PHARMA)

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

More

Our Clients